To summarize their results, it can be concluded that CYP1B1 is critical in the development of Dfen-induced PAH and therefore can be a novel therapeutic target for PAH.62 Chi and coworkers last year investigated the contribution of CYP1B1 to the development of atherosclerosis and hypertension and associated pathogenesis in 8 week-old male apolipoprotein E-deficient (ApoE−/−/Cyp1b1+/+), and ApoE- and CYP1B1d deficient (ApoE−/−/Cyp1b1−/−) mice fed a normal or atherogenic diet for 12 weeks. This evidence concerns the gene CYP1B1 and hypertensive disorder.